ArticleFrontiers in immunology2022

Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.

Marina Alexandre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.